Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
September 2015
-
Media ReleaseNovartis lance « Novartis Access », une gamme de médicaments à prix abordables pour lutter contre les maladies chroniques dans les pays à faible revenuUne approche unique en son genre dans l'industrie de la santé, qui vise à rendre 15 médicaments plus facilement disponibles et plus accessibles pour traiter les maladies cardiovasculaires, le diabète…
-
Media ReleaseNovartis lanciert "Novartis Access", ein Portfolio von erschwinglichen Medikamenten zur Behandlung von chronischen Erkrankungen in Ländern mit niedrigen EinkommenNeuartiger Portfolioansatz in der Gesundheitsbranche mit dem Ziel, die Verfügbarkeit und Erschwinglichkeit von 15 Medikamenten gegen Herz-Kreislauf-Erkrankungen, Diabetes, Atemwegserkrankungen und…
-
Stopping free radicals at their source
Compounds that block the production of damaging molecules might shed light on their role in disease—and lead to new therapies.
-
Confronting the global spread of chronic disease
Chronic diseases like cancer and diabetes were once the preserve of wealthy countries but are now increasingly common in lower-income countries too as populations age and lifestyles change.
-
Media ReleaseSwissmedic approves Novartis' new heart failure medicine Entresto(TM)Decision by Swiss Health Authority follows US Food and Drug Administration (FDA) approval of Entresto in July, serves as an important reference approval for multiple other health authorities…
-
Malaria fighter rides bicycle into battle with disease
Healthcare worker Dismus Mwalukwanda is on the front line of the battle against malaria. Saving lives is his priority.
-
Putting patients first
Chinweike Ukomadu thinks that notions about clinicians turning their backs on patients when transitioning to industry are outdated.
-
Media ReleaseNovartis Foundation healthcare models and disease elimination programs showcased at ECTMIHTelemedicine pilot in rural Ghana demonstrated positive impact and improved primary health services as reported by nurses, midwives and patients Retrospective contact tracing of former leprosy…
-
Media ReleaseNovartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myelomaFarydak (panobinostat) combination is approved in the EU for patients with multiple myeloma who received >=2 prior regimens including bortezomib and IMiD[1] In clinical trials, Farydak…
-
Media ReleaseSandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United StatesLaunch follows March 6, 2015 FDA approval Sandoz One SourceTM offers patient support services The digital press release with multimedia content can be accessed here: Holzkirchen,…
-
Media ReleaseNovartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemiaRevolade is the first approved therapy in the EU for patients with severe aplastic anemia (SAA) who have not responded to other treatments Patients living with SAA, a rare blood disorder,…
-
Media ReleaseNovartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatmentsThe companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule Novartis and Amgen also plan…
Pagination
- ‹ Previous page
- 1
- …
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- …
- 151
- › Next page